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Tumor Drug Penetration Measurements Could 
Be the Neglected Piece of the Personalized 
Cancer Treatment Puzzle  
Imke H. Bartelink1,2,12, Ella F. Jones3, Sheerin K. Shahidi-Latham4, Pei Rong Evelyn Lee5, Yanan Zheng2, 
Paolo Vicini6, Laura van ‘t Veer5, Denise Wolf 5, Andrei Iagaru7, Deanna L. Kroetz8, Brendan Prideaux9, 
Cornelius Cilliers10, Greg M. Thurber10, Zena Wimana11,* and Geraldine Gebhart11,*
Precision medicine aims to use patient genomic, epigenomic, specific drug dose, and other data to define disease 
patterns that may potentially lead to an improved treatment outcome. Personalized dosing regimens based on tumor 
drug penetration can play a critical role in this approach. state- of- the- art techniques to measure tumor drug 
penetration focus on systemic exposure, tissue penetration, cellular or molecular engagement, and expression of 
pharmacological activity. using in silico methods, this information can be integrated to bridge the gap between the 
therapeutic regimen and the pharmacological link with clinical outcome. These methodologies are described, and 
challenges ahead are discussed. supported by many examples, this review shows how the combination of these 
techniques provides enhanced patient- specific information on drug accessibility at the tumor tissue level, target 
binding, and downstream pharmacology. our vision of how to apply tumor drug penetration measurements offers a 
roadmap for the clinical implementation of precision dosing.
Precision medicine in oncology entails tailored drug treatment for 
individual patients. Personalized dosing regimens based on tumor 
drug penetration play a critical role in this approach. Technologies 
necessary for this endeavor, such as in vivo molecular, functional 
imaging, and ex vivo mass spectrometry, have matured. Tools pro-
viding enhanced patient- specific information on drug accessibility 
at tumor tissue level, target binding, and downstream pharmacol-
ogy are crucial to understand exposure- response relationships and 
guide precision dosing to improve treatment outcome.
PRECISION DOSING AS A MISSING PIECE OF THE 
PERSONALIZED CANCER TREATMENT PUZZLE
Precision medicine aims to use patient’s genomic, epigenomic, spe-
cific drug dose, and other data to define disease patterns that may 
potentially lead to an improved treatment outcome.1 Advances in 
precision medicine have been especially apparent in the field of on-
cology. An increasing number of targeted and “classic” cytotoxic 
agents can now be tailored to patient’s cancer characteristics, such 
as targeting the BCR- ABL fusion gene translocation in chronic 
myelogenous leukemia or dose reduction in polymorphism in 
enzymes involved in drug metabolism to reduce the risk of tox-
icity (e.g., UGT1A1*28 in irinotecan- based chemotherapy). In 
addition, some progress has been made to identify biomarkers that 
predict response to these agents. The human epidermal growth 
factor receptor 2 (HER2; also known as ERBB2/neu) has been 
one of the most well- documented successes in targeted cancer 
treatment. The HER2 gene is amplified in 15–20% of patients 
with breast cancer. The approval of HER2 targeted agents, led 
by trastuzumab in 1998, has improved outcomes in curative and 
noncurative breast cancers.2 Despite the success of targeted agents, 
such as those for HER2, improved long- term outcomes from pre-
cision medicine are still comparatively rare, with over 600,000 
Americans expected to die of cancer in 2018,3 and a predicted 
global burden of 13 million cancer deaths by 2030.4
A potential missing piece of the puzzle for precision medicine 
in cancer treatment may be an integrated “precision dosing” ap-
proach that tailors to patients’ tumor characteristics, as well as the 
extent of drug penetration in tumor tissue. In current dose escala-
tion study designs, a correlation is sought between treatment dos-
age or systemic (plasma) exposure and treatment response.5 Most 
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often, drugs are assumed to distribute relatively homogeneously in 
the tumor tissue. However, distribution of drugs into tumor tissue 
is in fact highly variable and may not correlate with dose or plasma 
concentrations. Such variability of drug penetration into tumor 
tissues may result in suboptimal treatment responses and yet its sig-
nificance is often neglected.
Thus, an important parameter in precision dosing is drug tumor 
penetration, which can be assessed by measuring accessibility of 
the target and drug penetration in tumors at macroscopic and/or 
microscopic levels. At the macroscopic level, drug penetration is 
often heterogeneous within one single tumor lesion and even more 
so across different metastatic sites in the same patient. At the mi-
croscopic level, sanctuary sites may result in heterogeneity in drug 
concentrations leading to a proportion of neoplastic cells not re-
ceiving the required therapeutic dose. Anticancer drug distribution 
will be investigated at four levels, in the context of drug accessibil-
ity and downstream pharmacologic effects (Figure 1), bridging the 
gap between drug dose and the pharmacological link with a solid 
tumor’s clinical outcome.
In this review, we will focus on the state- of- the- art tools, includ-
ing imaging techniques that provide patient- specific information 
on drug accessibility at the tumor tissue level, target binding, and 
downstream pharmacology in the context of precision dosing. 
Although these four drug distribution levels resemble the “three 
pillars of survival” framework, described by others,6 that includes 
drug exposure at the target site, target binding, and expression of 
pharmacological activity, additional consideration of spatial drug 
distribution in tumor tissue is added here. These four levels and 
their key considerations are further described below.
Systemic drug exposure
Assessment of systemic exposure ensures that the drug achieves a 
blood concentration during treatment that, in principle, permits 
optimal penetration and target binding into the tumor tissue, al-
lowing selection of a dose with the best probability to reach the 
maximal receptor occupancy in the tumor.7 Ideally, this would 
be the dose that results in the number of bound target receptors/ 
proteins in the tumor close to the maximum attainable, which 
is not always the maximum tolerated dose. Below, we discuss 
separately assessment of systemic exposure from measurements at 
the site of action (tumor tissue).
Tumor tissue drug penetration
At the tissue level, state- of- the- art techniques may be used to visual-
ize whether the drug is able to homogeneously distribute through-
out the tumor. A range of factors (e.g., vascularity, hypoxia, or drug 
efflux transporters) may influence drug penetration, depending 
on characteristics of the drug. For immunotherapies, where im-
mune cells are the effectors, the presence of specific immune cells 
and/or ligands in relation/proximity to tumor cells may affect the 
immune function and subsequent outcomes.8,9 These studies sug-
gest that before onset of an immune response, the presence and co-
localization of immune and tumor cells, should be assessed,8,9 in 
addition to drug tissue penetration. Changes in the tumor micro-
environment in response to drug treatment can be investigated. 
Last, for small molecules, the free fraction of the drug (i.e., the 
pharmacologically active fraction) may be different in tissues vs. 
the circulation, and, therefore, whenever possible, total and free 
drug concentrations should be measured.6
Cellular/molecular target engagement
At the cellular/molecular level, it is possible to assess the presence 
and accessibility of the target in the right conformation to allow 
drug binding (i.e., target engagement).10 As such, drug binding 
and target availability should be assessed within and across tumor 
lesions. Furthermore, for some drugs, it is important to assess tem-
poral changes in drug- target engagement. For example, when drug 
binding results in target internalization and the pharmacologic 
effect causes target downregulation or upregulation.
Expression of pharmacological activity
Biomarkers that reflect downstream disease cascading effects or 
treatment effects can also be measured through target binding at 
the site of action. These distal measurements of pharmacodynam-
ics (PDs) can indirectly demonstrate that sufficient levels of target 
modulation are being achieved at the site of action, in addition to 
providing a bridge toward quantification of drug efficacy and/or 
resistance.6
Figure 1 The pathway of drug administration to the tumor response is affected by tumor drug penetration at four levels: (1) the systemic level 
(the concentration of the drug in the blood pool, which determines how much of the drug is available for tumor penetration), (2) the tissue level 
(e.g., is the drug able to distribute throughout the tumor tissue, as influenced by the tumor microenvironment), (3) the cellular or molecular 
engagement level (where the drug is able to engage and interact with its target at the cellular/molecular level, a proximal or direct measure 
of drug mechanism of action), and (4) the expression of pharmacological activity following target engagement (a distal or indirect measure of 
drug pharmacodynamics). All these levels will be affected by responses to treatment (bottom).
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A multitude of state- of- the- art technologies can be applied to 
assess the four levels of drug penetration, as shown in Table 1. Each 
of these techniques differs in the information provided and its po-
tential role to inform clinical decision making and to guide optimal 
treatment strategies. We will mostly discuss implications for large 
molecules, although many of these concepts hold for, and can be 
extended to, small molecules as well. Techniques for drug charac-
teristics to improve drug penetration at each level (e.g., association 
to albumin to prolong systemic half- life, convection- enhanced de-
livery to improve tumor tissue penetration or changing affinity to 
the target to enhance target engagement) are beyond the scope of 
this article.11–13
As each of these four levels of biological organization is linked, 
information acquired from each component cannot be viewed 
separately. In addition, dosing recommendations require coupling 
quantification of heterogeneity in drug penetration and target en-
gagement with a drug’s PD link and long- term outcome. In silico 
methods can help bridge the gap from all these data into a more 
comprehensive understanding. Modeling and simulation can be 
applied to integrate available information on accessibility, target 
engagement, PD effects, and outcomes at multiple scales.14 In on-
cology, the previously proposed concept of model- informed preci-
sion dosing (MIPD)15 can be extended to include data from drug 
penetration studies. When properly validated, these models can be 
used in principle to predict and individualize doses.
STUDYING SYSTEMIC EXPOSURE: ILLUSTRATION AND 
TOOLS
As mentioned previously, drugs need to achieve systemic concen-
trations in the blood that permit adequate penetration and target 
binding into the tumor tissues.7 Assessment of drug concentra-
tion in blood or plasma alone (plasma pharmacokinetics (PKs)) 
may provide valuable information to guide drug dosing. PKs can 
be influenced by factors related to the patient, such as age, body 
weight, activity of drug transporters and metabolizing enzymes, 
and renal or liver function. Additionally, for monoclonal anti-
bodies or other large molecules, target binding, immunogenicity, 
affinity for the neonatal Fc receptor, nonspecific uptake followed 
by proteolytic degradation and catabolism, and deconjugation de-
termine the plasma PK- time profile.16 Furthermore, these plasma 
PK profiles can be profoundly different depending on the drug 
dose administered to the patient. At a low dose, nontarget specific 
(e.g., Fc receptor in liver) or nontumor but specific (e.g., circulat-
ing target in blood) binding may decrease the drug’s systemic ex-
posure, leading to less drug target binding at the tumor site (the 
so- called antigen sink). Higher doses may saturate the nonspecific 
binding sites, and lead to relatively high, nondose- proportionate, 
increases in systemic exposure compared to low doses, an effect 
called target- mediated drug disposition (TMDD).17 Therefore, 
evidence of nonlinear clearance by assessment of plasma PK pro-
files of monoclonal antibodies and other high affinity drugs can 
sometimes be used as a tool to predict the maximum binding ca-
pacity of the accessible drug target.7
State- of- the- art tools can be used to assess systemic exposure. 
During drug development, plasma PK profiles are routinely as-
sessed using techniques, such as liquid chromatography mass 
spectrometry (LC- MS), for small molecules or immunoassays for 
monoclonal antibodies. Thus, validated methods for measuring 
drug concentrations in blood should be available during drug de-
velopment. Less commonly, positron emission tomography (PET) 
imaging with radiolabeled drugs has been applied to quantify sys-
temic exposure and TMDD.
By way of example, an 89Zr- trastuzumab PET imaging study18 
demonstrates the interplay between systemic and tumor exposure 
in the presence of nonspecific binding resulting in large tissue sinks. 
This study showed that reaching a minimal systemic exposure is 
necessary to improve drug penetration into the tumor and engage 
the target.18 At 10 mg (1 mCi) tracer dose, rapid 89Zr- trastuzumab 
clearance was observed in trastuzumab naïve patients, and only 
after administration of 50 mg of 89Zr- trastuzumab (replenished 
with nonradioactive trastuzumab), tumor penetrance was observed 
using PET imaging, indicating the ability to overcome the normal 
tissue sink. In patients undergoing treatment with trastuzumab 
(up to 6 mg/kg) at the time of tracer injection, a dose of 10 mg 
tracer was sufficient to indicate tumor distribution, suggesting that 
during treatment, some saturation of (nonspecific) drug’s elimina-
tion pathways (e.g., via catabolism or plasma levels of extracellular 
domains shed by HER2) occurs. This also indicates that there are 
remaining free receptors in the tumor (we discuss saturation of the 
tumor sink in the next section).
Among many reported studies, one example of using TMDD 
to optimize dosing in drug development is shown in the analysis 
of the early phase study of RG7356, an anti- CD44 humanized an-
tibody, in patients with acute myeloid leukemia.19 At low doses, 
nonlinear PK was observed, which plateaued at 1,200 mg, at which 
point the maximum binding capacity of the accessible target was 
reached. This dose, as opposed to the maximum tolerated dose, was 
used to define the optimal dose for further phase II studies.19
This methodology is directly applicable to drug development: 
in 2017, the European Medicines Agency suggested in EMEA/
CHMP/SWP/28367/07, revision 1, assessment of target satu-
ration in early phase clinical trials and proposed that, instead of 
maximum tolerated dose, “maximum exposure” is considered, that 
provides complete inhibition or activation of the target and no fur-
ther therapeutic effect is to be expected by increasing the dose.
In contrast to the TMDD characterization in the 89Zr- 
trastuzumab and RG7356 examples, the PK profile of monoclonal 
antibodies in blood at clinical doses (at maximum binding capac-
ity) may be prognostic of disease rather than predictive of the bind-
ing capacity. Post hoc analyses of trastuzumab in a phase III study in 
gastric cancer (ToGa) showed that patients in the lowest quartile 
of trastuzumab serum trough concentration had shorter overall 
survival than patients in the higher serum trough concentration 
quartiles.20 More recently, clearance of the immunotherapeutic 
monoclonal antibody, nivolumab (a programmed cell death 1 (PD- 
1) blocking immunotherapeutic antibody) was shown to decrease 
when patients responded to therapy,21 and durvalumab (a PD- L1 
blocking antibody) change in clearance over time correlated with 
the change in tumor size during therapy and with the decrease in 
nonspecific protein catabolic rate in patients who benefited from 
therapy.22 This correlation suggests that the steep drug exposure- 
tumor response relationship observed in these studies may be 
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Table 1 State- of- the- art technologies that can be applied to assess specific aspects of drug penetration related to the 
systemic level, the tumor tissue level, and the cellular or molecular level
levels aim
Tools
Potential clinical 
relevance examplesmacroscopic level microscopic level
1. Systemic 
exposure
Ensure optimal 
bioavailability in 
blood to reach the 
maximal binding 
capacity in tumor 
tissues
* PK measurements 
in blood:
✓ Immunoassays for 
large molecules
✓ LC-MS(MS)/HP-LC 
for small 
molecules
✓ (radio)-labeled 
drugs
* Molecular imaging: 
✓ PET/SPECT 
(noninvasive)
Optimize dose 
(to overcome 
the tissue sink)
* 89Zr- Trastuzumab PET 
imaging and plasma PK to 
understand the tissue sink 
effect18 
* Plasma PK of RG7356, 
an anti- CD44 humanized 
antibody to define optimal 
dose for phase II study 
instead of MTD19 
* Linear plasma PK of 
nivolumab and durvalumab 
may reflect severity of the 
disease, and may not be 
useful to guide dose 
adjustments21,22
2. Tissue 
penetration
Assess tumor 
vascularization, 
immune infiltration 
and other factors in 
the tumor 
microenvironment
* (Labeled drug)- 
molecular imaging: 
✓ PET/SPECT
✓ DCE-MRI
✓ Angio-CT/SPECT
* Microdialysis
* Optical imaging
✓ IHC/
immunofluorescence 
✓ MALDI- MSI 
✓ Multiplexed ion 
beam imaging
Optimize 
treatment 
selection and 
understand 
mechanism of 
action
* Microdialysis of 
methotrexate40 
* Immunofluorescence 
imaging T- DM141 
* Fluorescent labeled 
bevacizumab/cetuximab- 
guided surgery44,45 
* Immunotherapies: 
radiolabeled PD- L146 or 
granzyme B PET imaging48
3. Cellular/
molecular 
concentrations
Ensure the 
presence/
accessibility of the 
target
* Labeled drug- 
molecular imaging:  
✓ PET/SPECT 
Imaging barriers of 
target engagement 
✓ Genomics
Biopsy- based assay to 
detect the presence of 
the target and the 
presence of factors 
that limit target:  
✓ IHC/
immunofluorescence
Optimize 
treatment 
selection
Macroscopic imaging:  
* 89Zr trastuzumab and 
T- DM149 
* Dose escalation guided 
by89Zr cetuximab50 
* Somatostatin receptor 
imaging (e.g., 68Ga for 
imaging and 177Lu- Dotatate 
treatment)54 
Interference factors:  
* ICD/ECD HER2 
expression58 
MUC4 and trastuzumab60 
* TAM uptake of lipidic 
nanoparticles63 
* ABCB1 polymorphism 
anthracycline and 
cytarabine67
4. Expression of 
pharmacology
Ensure that 
sufficient target 
modulation has 
been achieved, 
assess drug 
efficacy and predict 
drug resistance
Molecular imaging:  
* PET/SPECT
* Imaging of PD 
markers 
✓ For example, 
platinum adduct by 
immunofluorescence
Change 
treatments, and 
optimize dosing
* 18F- 
fluorodihydrotestosterone 
androgen receptor imaging 
post apalutamide70 and 
enzalutamide69 
* 18FES imaging post- 
RAD1901/fulvestrant/Z- 
endoxifen73–76 
* 89Zr trastuzumab HER2 
response imaging post- 
HSP90 inhibitor78 
* Platinum adducts after 
carboplatin 
administration79,81,82
18FES, FES16α- [18F]- fluoro- 17β- estradiol; CT, computed tomography; DCE- MRI, dynamic contrast- enhanced magnetic resonance imaging; HP- LC, high- 
performance liquid chromatography; HSP90, heat shock protein 90; ICD/ECD HER2, intracellular or extracellular domains of the human epidermal growth factor 
receptor; IHC, immunohistochemistry; LC- MS, liquid chromatography- mass spectrometry; MALDI- MSI, matrix- assisted laser desorption ionization mass 
spectrometry imaging; MTD, maximum tolerated dose; PD, pharmacodynamic; PD- L1, programmed cell death- ligand 1; PET, positron emission tomography; PK, 
pharmacokinetics; SPECT, single photon emission computed tomography; TAM, tumor- associated macrophage; T- DM1, ado- trastuzumab emtansine.
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confounded by prognosis and treatment outcome.21,22 Reasons for 
the correlation between PK and performance status of the patient 
is an active area of research and needs to be studied further. It may 
be related to cachexia, antibody cleavage by the tumor or systemic 
inflammation.21 These monoclonal antibodies when used in clin-
ical doses generally show linear and dose- proportional pharmaco-
kinetics.21–23 Therefore, it is less likely that TMDD contributed to 
the disease- specific PK. As a result, increasing the drug dose based 
on exposure at linear plasma PK in patients with poorer prognostic 
factors may not improve their outcomes. The HELOISE study – 
a randomized study of high- dose trastuzumab (8 mg/kg + 10 mg/
kg) vs. standard of care trastuzumab (8 mg/kg + 6 mg/kg) – in-
deed showed that higher doses of trastuzumab in patients predicted 
to have low exposure (based on an Eastern Cooperative Oncology 
Group score of 2) did not improve outcomes.24
STUDYING TUMOR TISSUE PENETRATION: ILLUSTRATION 
AND TOOLS
Tumor tissue penetration is largely determined by a variety of 
factors in the tumor microenvironment.25 This includes tumor 
vascular architecture, the composition and structure of the ex-
tracellular matrix, and the stroma. Aggressive proliferation of 
tumor cells and associated overexpression of pro- angiogenic fac-
tors often leads to the development of poorly organized vascular 
and lymphatic architecture in tumors. As a result, the irregular 
blood flow and increased interstitial fluid pressure can severely 
affect drug distribution within the tumor and limit delivery of an-
ticancer drugs to cells distal from the vasculature, depending on 
characteristics of the drugs. Stroma proteins in the extracellular 
matrix may give rise to a dense network of tumor matrix compo-
nents that forms a physical barrier to tumor drug penetration.26 
Small, hydrophilic compounds with low protein binding are ex-
pected to diffuse rapidly from the cellular rim into less vascular-
ized or necrotic tissues (as seen in caseous tuberculosis),27 whereas 
drugs with high lipophilicity, poor solubility, and high number of 
aromatic rings are more likely to bind and not diffuse.27 For mac-
romolecules, extravasation across the relatively permeable tumor 
vasculature is a limiting step for tumor penetration.7,25
State- of- the- art tools can be used to assess tumor tissue pen-
etration. At a macroscopic level, information on vascularity and 
vascular- related drug uptake can be obtained using dynamic 
contrast- enhanced (DCE) magnetic resonance imaging (MRI), 
PET, or single photon emission computed tomography (SPECT) 
perfusion studies. In these noninvasive methods, molecules that 
pass through the blood vessel walls of the tumor and enter the 
extracellular extravascular space without penetrating the cellular 
membrane can provide information on vascular- related drug uptake 
(e.g., blood volume, blood flow, and/or vascular permeability).28 
In DCE MRI, gadolinium chelates are contrast agents that alter 
the relaxation time of water protons in tissues to create a contrast 
in imaging. In PET or SPECT, radiolabeled tracers, such as 15O- 
water, 13N- ammonia for PET,29 and 99mTc- sestamibi for SPECT,30 
are used. In addition, microdialysis, a semi- invasive method can be 
used. During microdialysis, a catheter is placed in the vicinity of the 
tumor to allow measurement of the extracellular, nonprotein bound 
drug in accessible solid tumors at multiple timepoints postdose.31
At a microscopic level, large molecules or nonionizable agents 
can be analyzed in a section of the biopsy by immunofluorescence 
(IF) or multiplexed ion beam imaging, if secondary fluorescent 
antibodies or those contain isotopically pure elemental metal are 
available.32,33 To assess the spatial distribution of unlabeled small 
molecules (and their metabolites) in clinical tissue samples, matrix- 
assisted laser desorption ionization- mass spectrometry imaging 
(MALDI- MSI) can be applied34,35 to a section of a fresh frozen 
 biopsies.35,36 By multiplexing (multiple stains per section), other 
histological assays can be applied to detect other factors in the 
tumor microenvironment influencing drug penetration (e.g., 
CD31 immunohistochemistry (IHC) staining for blood vessels).
Recently, it has become feasible to study microscopic drug pen-
etration in in vitro cultured tumor cells in a 3D setting, resem-
bling the in vivo architecture and tumor microenvironment of the 
tumor.37 Such tumor- on- a- chip models are a subset of organ- on- 
a- chip models. Therefore, tumor- on- a- chip models can easily be 
combined with imaging (e.g., confocal microscopy) to study how 
microscopic drug penetration is influenced (e.g., interstitial flow), 
by the leakiness of the endothelial barrier or the density of the 
collagen matrix.37 As an example, a tumor- on- a- chip was used for 
screening optimal nanoparticle designs prior to in vivo studies.38 In 
this study, the effect of nanoparticle size and interstitial flow rate 
on tissue accumulation was confirmed in murine tumor models.38
In the clinical setting, optical imaging can be used to assess tis-
sue penetration. In fluorescence- guided surgery, fluorescently la-
beled drugs are administered prior to surgery to delineate tumor 
margin and to visualize drug penetration in solid tumors.39 The 
optical technique can also be used to visualize the penetration of 
the fluorescently labeled drug in the resected tumor. An advantage 
of using surgical material to understand drug penetration over a 
2D biopsy section- based assay is that the latter may be representa-
tive only of the immediate tissue surroundings. Multiple sections 
obtained during fluorescence- guided surgery may provide macro-
scopic and microscopic 3D information. Although the informa-
tion on microscopic drug penetration may not be applied directly 
to optimize dosing in the same patient, data from these studies may 
help dose optimization in patients with similar disease character-
istics and contribute to the understanding of mechanisms of drug 
penetration.
An example of macroscopic quantification by microdialysis is 
provided by a study measuring methotrexate in the extracellular 
fluid of brain tumors of four patients with recurrent high- grade gli-
omas after high- dose methotrexate (12 g/m2).40 Methotrexate lev-
els were considerably higher in two patients who showed contrast 
enhancing regions of the brain by DCE MRI compared to two pa-
tients with nonenhancing brain regions.40 The results of this small 
study suggest that methotrexate penetration into brain tumors is 
variable and that combining drug measurements with DCE MRI 
can be applied to predict drug penetration as a function of tumor 
perfusion.40 That being said, clinical studies using microdialysis are 
currently too small to provide information on whether drug pene-
tration relates with clinical outcomes.
Another example of assessing spatial drug gradients at a mi-
croscopic level with potential clinical implications has been pro-
vided for ado- trastuzumab emtansine (T- DM1), an antibody-drug 
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conjugate (ADC) that binds to receptors of cells in close proximity 
to the vasculature.41,42 The T- DM1 drug penetration images in an 
HER2- positive xenograft mouse model (Figure 2a–c) show that, 
at clinically relevant doses, the binding of T- DM1 to the HER2 
target occurs at a faster rate than diffusion across tissues, with the 
drug becoming immobilized immediately outside of blood vessels, 
a phenomenon commonly referred to as the “binding site barrier.” 
Lowering the drug payload to antibody ratio, by co- administering 
unconjugated antibody (trastuzumab) with T- DM1 at the same 
payload dose level, caused a larger fraction of antibody to compete 
and occupy receptors. This in turn allowed binding and internal-
ization of the toxic payload to receptors across a larger number 
of tumor cells highly expressing the HER2 target (Figure 2d–f). 
This method of lowering the drug payload to antibody ratio to 
improve homogeneity in payload penetration among tumor cells 
has been shown to increase response in the animals.41,43 Although 
this study visualizes limited penetration of an ADC with a highly 
potent payload when target expression is high, the best strategy to 
homogenize the penetration of ADCs in patient tumors should be 
studied further in patients and furthermore correlated with patient 
outcome.
Two recent studies sought to visualize microscopic drug pene-
tration in resected tissues after fluorescence- guided surgery. The 
accumulation of fluorescently labeled bevacizumab, an antivascu-
lar endothelial growth factor antibody, was found to correlate with 
the pathological Bloom–Richardson–Elston tumor grade (a score 
that indicates cancer aggressiveness)44 in resected breast tissues 
from 19 patients with breast cancer. In another study, the level of 
fluorescently labeled cetuximab, an anti- epidermal growth factor 
receptor (EGFR), accumulated within the resected tumor tissues 
Figure 2 At clinically relevant doses, the binding of ado- trastuzumab emtansine (T- DM1) to human epidermal growth factor receptor 2 (HER2) 
expressing tumor cells is limited to the cells near functional blood vessels, and much higher doses are needed to provide a more homogeneous 
penetration, as shown at the microscopic level in an HER2 expressing xenograft tumor model (NCI- N87 xenograft). (a) An immunofluorescence 
image of a tumor 24 hours following administration of 3.6 mg/kg of Alexa Fluor 680 tagged T- DM1 - a dose comparable to the dose used in 
patients - to nude mice bearing NCI- N87 flank tumors (green). Immunofluorescence staining with CD31- AF555 (red) shows tumor vasculature, and 
intravenous administration and visualization of Hoechst 33342 shows functional vessels (blue) using multiplexed imaging. (b) HER2 expression 
(ex vivo staining with trastuzumab) in the same tumor section (white) and enlarged (c), indicating the uptake in the tumor was only sufficient to 
target a few cell layers. Images d, e, f show the same visualizations 24 hours following administration of 3.6 mg/kg of Alexa Fluor 680 tagged 
T- DM1 and 10.8 mg/kg unlabeled trastuzumab (14.4 mg/kg total in a 1:3 ratio), indicating a more homogenous tumor penetration of T- DM1. 
This dose reached many cells but did not occupy all accessible receptors in the tumor. Much higher doses up to 32 mg/kg of a combination of 
T- DM1 and trastuzumab, in a 1:8 ratio (the latter to avoid antibody- drug conjugate toxicity and improve penetration) were required in this animal 
model (with high HER2 expression, ~1 million receptors/cell) to reach all cells (data not shown). Red = CD31 +  staining; green = 3.6 mg/kg T- 
DM1- AlexaFluor 680 (a–c) or 3.6 mg/kg T- DM1- AlexaFluor 680 + 10.8 mg/kg untagged trastuzumab (d–f); white = HER2 (trastuzumab labeling of 
histology slide); blue = functional vessels (intravenous Hoechst 33342). [Colour figure can be viewed at wileyonlinelibrary.com]
(a) (b) (c)
(d) (e) (f)
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of nine patients with head and neck squamous cell carcinoma, was 
correlated with cytokeratin (a measure of tumor density), EGFR 
expression, and factor VIII (vascular density).45 The latter bio-
markers show that biological characteristics of the tumor may in-
fluence antibody (peri- ) tumoral distribution and target binding.
Immunotherapy poses new challenges for assessing drug efficacy. 
The key event for successful immunotherapies is the ability to at-
tract both the drug and the immune cells into the tumor microen-
vironment; for example, immune cells, as opposed to drugs, thus 
become the mediator of antitumor effect. Tumor expression of 
PD- L1 might be required for response to anti–PD- 1/programmed 
cell death- ligand 1 (PD- L1)- targeted therapies, but also the acces-
sibility of tumor- antigen specific (PD- 1 suppressed) immune cells 
to the tumor space is another important driver of immune check-
point inhibitor efficacy. In patients with melanoma, the spatial dis-
tribution and colocalization of immune cells immediately adjacent 
to PD- 1/PD- L1 expressing tumor cells correlated with outcome of 
anti- PD1 therapy.8,9 The distribution was assessed using histolog-
ical sections of tumor biopsies collected from patients before anti- 
PD- 1 therapy with outcome of anti- PD- 1 therapy.8,9 Molecular 
imaging of immunotherapies may show the presence and accessi-
bility of the target, but its use is still in its infancy.46 PET imaging 
with 89Zr- atezolizumab in an imaging trial NCT02453984 or with 
89Zr- pembrolizumab in another trial NCT02760225 prior to the 
start of immunotherapy may be able to demonstrate the value of 
immune- PET imaging for patient selection. Furthermore, the pres-
ence of other immune- suppressive cells in the tumor microenviron-
ment may predict resistance to immunotherapy.47 Multiple other 
cell types may contribute to tumor- mediated immune suppression, 
including regulatory T cells, type 2 natural killer T cells, tumor- 
associated macrophages (TAMs), tumor- associated neutrophils, 
and myeloid- derived suppressor cells and, therefore, may influence 
the efficacy of PD- 1- based therapies.47 Importantly, an imaging 
biomarker of cytotoxic T- cell activity may be more valuable for 
predicting response to cancer immunotherapy than biomarkers 
characterizing the entire immune infiltrate. Accordingly, PET im-
aging of radiolabeled granzyme B, a protease released from CD8+ 
T cells inducing apoptotic death of target cells, is currently under 
development.48 In conclusion, a combination of target engage-
ment/activation imaging and assessment of spatial heterogeneity 
in PD- 1/PD- L1 expressing immune cells and tumor cells in the 
tumor microenvironment at the microscopic level may advance the 
prediction of response to immunotherapies.
STUDYING TARGET BINDING AT A CELLULAR/MOLECULAR 
LEVEL: ILLUSTRATION AND TOOLS
When systemic exposure (in blood) has been optimized and the 
drug has been shown to penetrate tumor tissues, the subsequent 
step is to demonstrate target engagement.
Depending on the mechanism of action, target engagement can 
occur either intracellularly or extracellularly. For targeted drugs re-
quiring internalization to be effective, intracellular accumulation 
should also be assessed.
State- of- the- art tools can be used to assess target engagement. 
At a macroscopic level, in vivo whole- body imaging (e.g., molecular 
imaging) may help to determine the presence of the target in the 
tumor lesion as well as the heterogeneity of the target expression 
across all lesions. Noninvasive in vivo imaging can be combined 
with standard pathology methods to provide absolute expression 
level (receptors/cell).
Molecular imaging has been applied to study target engagement 
through the visualization of the target’s presence and accessibility 
(including the right conformation). It has largely been based on 
radionuclide imaging in the form of SPECT and/or PET. Other 
techniques, such as optical, spectroscopy, or photo- acoustic imag-
ing, are also in clinical development.
At a microscopic level, standard pathology procedures on a 
tumor sample (ex vivo), such as immunohistochemistry (IHC) or 
immunofluorescence (IF), gene, and RNA or protein expression 
measurements, are used to determine the presence of targets for 
therapy. However, these measurements should be appropriately 
validated allowing some quantification of these markers, as de-
scribed in the Challenges/Prospects section.
Target engagement imaging could allow optimal drug selection 
and drug dosing.
One example of optimal drug selection is the ZEPHIR trial 
(NCT01565200). It is the first prospective clinical study that 
sought to explore the clinical utility of HER2 imaging as a pre-
dictive biomarker to optimize treatment selection in advanced 
HER2- positive breast cancer. The study examined if low/absent 
radiolabeled trastuzumab tumor engagement, due to lack of target 
accessibility and/or drug penetration, could predict poor treat-
ment response to HER2 targeted therapy, in this case, T- DM1.49
In the trial, 89Zr- trastuzumab PET/computed tomography (CT; 
HER2 PET/CT) and 18F- fluorodeoxyglucose (FDG) PET/CT im-
aging were performed at baseline prior to T- DM1 initiation. In an 
IHC/fluorescence in situ hybridization (FISH) confirmed HER2- 
positive population, one- third of patients were found to be “HER2- 
negative” based on HER2 PET/CT. Accordingly, the median time 
to treatment failure of the latter group was three times shorter than 
the ones with a more homogenously positive HER2 PET/CT. 
Figure 3 shows a patient in which 89Zr- trastuzumab drug does not 
reach its anticipated target. This patient’s lung metastasis was tested 
HER2- positive by IHC, but HER2 PET/CT showed a lack of pen-
etration into the biopsied tumor. Response imaging on18F- FDG 
PET/CT after three courses of T- DM1 showed progressive disease.
Two ongoing clinical trials (study NCT02117466 and 
NCT01691391) show that dosing based on imaging of target en-
gagement is feasible. In these studies, the uptake of 89Zr- cetuximab 
assessed at day 6 after treatment onset is tested as a potential predic-
tive biomarkers for early benefit of cetuximab as an EGFR targeted 
drug in treatment with colorectal cancer. The first results show that 
interpatient variability in PK and tumor uptake of 89Zr- cetuximab 
only allowed dose escalation of cetuximab in 6 of 44 patients with 
metastatic colorectal cancer.50
Another example is the use of target engagement for drug se-
lection in neuroendocrine tumors (NETs). Somatostatin receptor 
(SSTR)- based molecular imaging has been used to detect NETs 
overexpressing SSTRs (initially using SPECT and more recently 
also using PET) and for the selection of candidates for thera-
pies directed against these receptors. Moreover, SSTR  imaging 
may also be used to optimize drug dosing (i.e., dosimetry) 
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when radiolabeled somatostatin analogue based treatment (i.e., 
peptide- receptor radionuclide therapy (PRRT)) is considered in 
advanced, well- differentiated somatostatin expressing NETs.51–53 
In addition, PRRT can be used as theranostic,10 using the same 
peptide labeled with diagnostic nuclide, such as 68 Ga- , 111In for 
imaging, and 177Lu or 90Y for radiotherapy. However, the do-
simetry approach is still under debate due to conflicting results 
in dose- effect relationships.54,55 Most PRRTs are still given ac-
cording to a fixed activity administration scheme,56 or use pre-
treatment scans to adjust dosing based on organ uptake to avoid 
toxicity.57 In addition, randomized studies comparing fixed vs. 
tumor image- driven dosing are lacking.
Measurement of expression of the target may not always trans-
late into a correct prediction of target engagement due to many 
interfering factors. An example of a factor that precludes optimal 
target engagement prediction based on standardized target expres-
sion measurements comes from a comparison of HER2 epitopes. A 
recent study58 using a quantitative IF technique demonstrated the 
importance of the binding epitope on the target, in HER2- positive 
breast cancer. A comparison was made between quantification of 
HER2 based on its intracellular domain (ICD; one used for IHC in 
clinical setting) epitope vs. its extracellular domain (ECD; binding 
epitope of trastuzumab) and their relation to treatment outcome of 
adjuvant chemotherapy and trastuzumab. This comparison showed 
that ECD was the most important predictor for a favorable treat-
ment outcome, rather than ICD.58 This study shows that caution 
should be applied when opting to characterize binding to a target 
using molecular imaging tools binding an epitope different than the 
therapeutic. When available, optimizing the pathology platform for 
assessing target expression based on multiple epitopes or pathways 
can be used to optimize treatment selection, like for HER2 directed 
drugs against multiple epitopes or downstream pathways.
The presence of high molecular weight mucins may mask 
the binding epitope on the target and, thus, impede target en-
gagement. Transmembrane mucin MUC4 has been reported to 
hinder the accessibility and, hence, the binding of trastuzumab 
to HER2 ECD, thereby impairing sufficient binding of trastu-
zumab to tumor cells.59 Therefore, reducing MUC4- masking 
Figure 3 Lack of correlation between human epidermal growth factor receptor 2 (HER2) assessed by immunohistochemical (IHC) and 89Zr- 
trastuzumab uptake in the same lesion of a patient in the ZEPHIR trial (NCT01565200). An HER2- positive tumor of a patient with metastatic 
breast cancer with lung metastasis was visualized using (a) 18Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed 
tomography (CT), (a marker of tumor metabolism) but not with (b) HER2 PET/CT (non- significant tracer uptake). Pre- treatment (tx) biopsy of 
a right metastasis in the middle lobe (c) shows IHC 3 +  staining (antibody recognizing the intracellular domain of the receptor). Response 
assessment (d) with FDG- PET/CT shows progressive disease after three courses of ado- trastuzumab emtansine (T- DM1). [Colour figure can be 
viewed at wileyonlinelibrary.com]
Baseline FDG PET Baseline HER2 PET FDG PET post 3 T-DM1Pre-tx IHC
3+
Biopsied
lesion
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with mucolytic drugs improved HER2 accessibility, resulting in a 
higher antitumor  effect of trastuzumab in HER2/MUC4- positive 
xenograft models.60 Similarly, altered glycosylation in cancer cells 
increases sialic acids and carbohydrate structures called “tumor- 
associated carbohydrate antigens” within the cell surface’s sugar 
coating, or glycocalyx, which may prevent immune cells to trigger 
or evade immunological recognition. Targeting the glycocalyx by 
sialidase conjugation to trastuzumab has been shown to preclin-
ically enhance the cell- mediated cytotoxicity preclinically,61 and 
vaccines against tumor- associated carbohydrate antigens are being 
developed.62 Clinical studies are needed to show whether reducing 
mucin masking or targeting the glycocalyx is applicable in patients.
Uptake of drugs by TAMs could be another barrier to target 
engagement. Pegylated liposomes were taken up primarily by 
macrophages in the tumor, whereas the same liposomes contain-
ing anti- HER2 antibody on the surface distributed over HER2 
overexpressing tumor cells with similar overall tumor tissue 
 accumulation.63 Therefore, the interest for TAMs in oncology is 
not limited to their role in suppressing antitumor immune therapy 
response, but extends to the fact that they may limit drug target 
binding through macrophage- directed drug clearance64 especially 
of lipophilic drugs,27 or by removal of immunotherapeutic anti-
bodies from immune cells.65
Drug transporters add another layer of complexity in intracel-
lular target engagement.66 P- glycoprotein (ABCB1) and breast 
cancer resistance protein (ABCG2) have established roles in con-
ferring multidrug resistance by limiting intracellular drug accu-
mulation in tumor cells. For example, polymorphisms in these 
efflux transporters and an increase in messenger RNA expression 
correlated with relapse and survival in 263 Chinese patients with 
intermediate- risk acute myeloid leukemia treated with anthra-
cycline and cytarabine.67 However, up until now, it is unclear 
whether transporter- mediated drug efflux by P- glycoprotein and 
breast cancer resistance protein leading to reduced intracellular 
drug accumulation actually occurs in tumor cells in patients.68 
Imaging agents need to be developed to quantify drug accumula-
tion in tumor cells in patients. Unfortunately, the development of 
inhibitors of specific drug transporters has failed to provide bene-
fit in the clinic to date.68 A more targeted approach to stratify pa-
tients based on multidrug transporter expression and/or function 
should be considered. Further research is needed to understand 
how transporter expression can be used to provide information on 
dose selection.
STUDYING EXPRESSION OF PHARMACOLOGICAL ACTIVITY 
FOLLOWING TARGET BINDING: ILLUSTRATION AND TOOLS
We distinguish between proximal target binding and subsequent 
distal expression of pharmacological activity (e.g., antibody target 
binding vs. downstream signaling response). This distinction may 
clarify how the drug mechanism of action modulates the biolog-
ical effects following successful binding and provide insight into 
the drug’s downstream effects. This may inform the existence and 
extent of a pharmacological link with outcome. Pharmacological 
activity at the protein or RNA expression level or downstream 
pathway activation can be assessed using the tools as described in 
previous sections.
In recent first- in- human studies of drugs directed at 
the androgen receptor (AR), such as enzalutamide69 and 
apalutamide70 – two nonsteroidal anti- androgens – molecular 
imaging was used to determine the optimal biological dose. The 
uptake of 18F- fluoro- 5α- dihydrotestosterone (FDHT; an endog-
enous dihydrotestosterone analogue) reflects AR expression and 
binding capacity. Therefore, the PD biomarker FDHT in PET/
CT imaging gauges PD response to these treatments.69,70 Uptake 
of FDHT reached a plateau at a dose of 120 mg apalutamide70 and 
150 mg for enzolutamide,69 suggesting maximal AR binding capac-
ity and, thus, achievement of the optimal drug concentration. The 
recommended—and later US Food and Drug Administration- 
approved—dose of apalutamide based on this study was much 
lower than the maximum tolerated dose.70
The 16α- [18F]- fluoro- 17β- estradiol (18FES) imaging has been 
used to predict responders to endocrine therapies targeting the es-
tradiol receptor (ER): the absence of FES uptake at baseline may 
predict endocrine treatment failure in patients with ER- positive 
breast cancer.71,72 In a feasibility study assessing ER availability 
before and during fulvestrant treatment, incomplete reduction of 
the ER target was observed after fulvestrant administration in 6 
of 16 patients with metastatic breast cancer (38%).73 In addition, 
FES was used as a biomarker to assess efficacy of novel ER treat-
ments, such as Z- endoxifen (the most potent of the metabolites of 
tamoxifen), RAD1901 (a novel, oral, ER ligand), and GDC- 0810 
(a selective ER degrader).74–76 For the latter, a phase II study was 
designed with an optimal dose of GDC- 0810 selected using the 
ER target engagement measurements.76
HER2 imaging with 89Zr- trastuzumab might be a surrogate of 
the efficacy of novel agents like the heat shock protein 90 (HSP90) 
inhibitor luminespib (NVP- AUY922). HER2 is a sensitive client 
protein of HSP90, and was shown to be depleted by HSP90 in-
hibition with luminespib in preclinical experiments.77 The 89Zr- 
trastuzumab PET was used to determine the in vivo degradation 
of HER2 caused by the drug. The change between tumor uptake 
on baseline and early 89Zr- trastuzumab PET after 3 weeks of treat-
ment with this HSP90 inhibitor had a moderate positive correla-
tion with change in tumor size on CT after 8 weeks of treatment in 
29 lesions of 5 patients, showing that HER2 imaging can be used 
to assess target degradation and response to novel agents, such as 
luminespib.78
Another example of imaging PD markers is the measurement of 
platinum- adduct formation (the covalent binding of carboplatin/
cisplatin or oxaliplatin to nuclear DNA) by IF,79 by LC- MS80 or in-
ductively coupled plasma- mass spectrometry.81 Platinum adducts 
in tumors are highly variable between patients, and small studies 
show that these may be more predictive of treatment response than 
platinum exposures in plasma.79,81,82
THE ROLE OF MODELING AND SIMULATION TO INTEGRATE 
MULTISCALE INFORMATION AND PROVIDE DOSING 
GUIDANCE
To understand the effect of drug penetration at all levels on treat-
ment response, information obtained from multiple levels and at 
temporal scales needs to be simultaneously considered. Multiscale 
models integrating information of drug distribution in spatial and 
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temporal scales will be needed to understand macroscopic and mi-
croscopic distribution of drugs and to optimally guide personal-
ized dosing14 (Figure 4).
Preclinical information derived from either in vitro or in vivo 
experiments, such as receptor internalization rate, binding affinity, 
and the affinity for drug transporters (measured in cell culture), 
can be paired with clinical plasma PK,17 along with preclinical43 
and clinical imaging data,10,83 to simulate events at molecular, cel-
lular, and tissue levels based on data from imaging, blood samples, 
and biopsies (Figure 4, top). The diversity in the tumor environ-
ment should then be linked to spatial heterogeneity in the cellular 
states across the tumor.84 In addition, mechanistic information 
from preclinical pharmacology models can be used to further un-
derstand drug dose- drug penetration- drug activity relationships.85 
When experimental data containing spatial information are ob-
tained, image processing can reconstruct the relative order, geom-
etry, topology, patterns, and dynamics of the 2D tissue sections. A 
3D tumor is created, which can then be used to simulate temporal 
growth and evolution (Figure 4, middle).14 By integrating all drug 
penetration information into spatiotemporal models, (Figure 4, 
bottom) one can predict the dose needed for the optimal response 
(maximal binding of target receptors) using prior drug informa-
tion and data from both the individual and a similar population 
of patients. In such spatiotemporal models, the microscopic and 
macroscopic spatial scales as well as the temporal scales should be 
considered.14 These temporal scales may encompass milliseconds 
for molecular interactions, hours for PK changes, days for tumor 
growth, and weeks to years for disease evolution.14 In such a model, 
the effect of drug transporters and specific factors that hinder tar-
get engagement, or change target expression during treatment, can 
be tested at all spatiotemporal levels.
The PK/PD modeling approaches provide a powerful tool to 
integrate time- dependent exposure and response data to predict 
treatment outcomes.15 However, in most current PK/PD models, 
drugs are assumed to distribute homogeneously in the tumor tissue. 
To describe the spatial distribution of drugs in tumors, common 
mathematical models involving ordinary or partial differential 
equations or agent- based modeling can be applied.14 The agent- 
based modeling is an increasingly popular modeling approach in 
which individual discrete “agents” are simulated that can interact 
according to some prespecified rules; agents can simulate spatial 
heterogeneity by moving along a 3D lattice, thus accounting for 
spatial and temporal information.
An example of a multiscale model is the Oncosimulator.86 In 
this model, clinical, imaging, molecular, and treatment schedules 
are combined to predict response to anticancer treatments and 
radiotherapy.86 MRI images (T1 with contrast enhancement, T2, 
and T2 flair) of patients with nephroblastoma before treatment 
onset and after 4 weeks of chemotherapy were used to validate the 
model- predicted tumor size changes. Model- predicted tumor sizes 
were compared with an automated segmentation of the MRI scans 
of the tumors and with clinical experts’ annotation.86 Inclusion 
Figure 4 Drug development typically proceeds by optimizing molecular properties of target engagement and access (e.g., biophysical 
binding and cell culture methods) followed by preclinical studies (ex vivo and in vivo measurements) and eventual human trials to determine 
clinical endpoints. Here, we present a vision of how we can use in silico methods to help bridge the gap between these methods to a more 
comprehensive understanding (top). These same approaches can be used to integrate personalized data (imaging, plasma clearance, and 
biopsies) with computational models containing preclinical and in vitro data to develop personalized dosing schemes (bottom). MS, mass 
spectrometry. [Colour figure can be viewed at wileyonlinelibrary.com]
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of models assessing the heterogeneity in tumor drug penetration 
in the Oncosimulator models may further improve the predictive 
value of the models. Other examples show how the spatial mea-
surements at three levels (systemic, tissue, and cellular level) can be 
combined. First, Ribba et al.87 used longitudinal data from multi-
ple state- of- the- art techniques to describe the tumor drug penetra-
tion of an immune- stimulatory drug Cergutuzumab amunaleukin. 
The nonlinear plasma concentration- time profiles and interleukin- 
2R- positive cells in peripheral blood of 50 patients were described 
using a TMDD model. A Krogh cylinder model (a model de-
scribing the spatial drug gradients from the tumor blood vessels) 
was used to describe the extravasation and diffusion of the drug, 
thereby predicting the expansion of the target cells in the tumor 
by immune activation. The predicted tumor drug penetration was 
validated using measurements of drug uptake in tumor lesions fol-
lowing administration of 89Zr- labeled Cergutuzumab amunaleu-
kin at 3 sequential timepoints in 14 patients. The final model was 
used to identify a dosing regimen with an optimal antibody tumor 
uptake in patients. Quantification of radiolabeled drugs per tumor 
site was accomplished here using an uptake scaling factor at the 
level of the extravasation processes, the rate limiting process of drug 
uptake. In future studies, such a quantification can conceivably be 
expanded by using tumor vascularization and expression data to 
determine the temporal microscopic distribution and response in 
each lesion.41 Such models could be extended by using information 
about the molecular aspects of the drug of interest. For example 
Checkley et al.88 used a cell cycle model and incorporated mech-
anisms of DNA damage and repair based on in vitro and in vivo 
tumor growth experiments to describe the effects of an ataxia telan-
giectasia and rad3-related (ATR) kinase inhibitor (AZD6738) and 
ionizing radiation. When information about mechanism of action 
and spatial drug distribution at all four levels are combined, mod-
els, such as those we presented, can bridge the gap between preclin-
ical experiments and clinical observations. When these models are 
correlated with clinical outcomes, the model structures may have 
re- usability across drugs with the same mechanistical properties.89
CHALLENGES/PROSPECTS
As all four levels of biological organization we described are 
linked, understanding each aspect will inevitably lead to a cascade 
of interactions. To make precision dosing a clinical reality, optimi-
zation of all these processes is needed simultaneously.
Assessment of systemic exposure can become an integral part 
of precision dosing when adequate PK assays and data analyses are 
used to estimate the individual PK- profiles in blood. Nonlinear 
mixed effects models combine structural models with estimates 
of nested variability in clinical observations, enabling estimation 
of means and variances of the statistical distributions of model 
parameters. Such a population approach may be used to calculate 
individual PK- parameters in blood, limiting the need to design and 
plan for very specific sampling strategies. Moreover, this approach 
utilizes both individual PK parameters and population estimates to 
quantify nonlinearity in drug clearance and TMDD.
Assessment of drug tissue penetration can become an inte-
gral part of precision dosing when carefully timed tumor biop-
sies during treatment or alternative noninvasive techniques are 
available. A challenge when assessing drug exposures is that the 
biopsy should be performed at specific times after dosing, chosen 
to be relevant to the temporal evolution of the drug’s action. In 
addition, in a significant proportion of patients, biopsies cannot 
be performed, owing to difficult tumor (metastasis) locations and 
low percentage of cancer cells in some samples,90 specifically when 
these biopsies are taken during an effective treatment. Although 
the I- SPY 2 TRIAL shows that it may be feasible to take a biopsy 
during treatment,91 noninvasive techniques for macroscopic visual-
ization of drug penetration or combination with other techniques, 
such as fluorescence- guided surgery, may help collection of the op-
timal study samples. A limitation of techniques, such as image in-
tensities by MALDI- MSI, IHC, and immunofluorescence, is that 
the resulting images do not allow comparison between patients. 
These measurements rely heavily on the specific settings used and 
show large variability among different assessments.92 Efforts to-
ward quantitative MALDI- MSI measurements of drug have been 
demonstrated in preclinical samples93; however, drug detection 
still requires the MALDI- MSI methods be developed and opti-
mized for each drug of interest. An example that standardization of 
MALDI- MSI is possible is provided in the application of MALDI 
to detect the presence of bacteria in infectious diseases.94 If appro-
priately validated, estimated absolute levels (e.g., drug or proteins/
cell) would provide a dramatic improvement in uniformity across 
laboratories and comparisons between targets.
Target engagement molecular imaging can be used to perform 
precision dosing when both feasibility and benefit are confirmed 
in prospective clinical trials. One of the limitations of target en-
gagement molecular imaging using PET/SPECT is the fact that 
radiolabeled molecules will irradiate the patient for a certain time 
conforming to the decay of the chosen radionuclide. Using long- 
lived radioisotopes, which are required for large molecules with 
long circulation time, will, therefore, result in a higher radiation 
dose to the patient. One approach to avoid this is to use smaller 
protein scaffolds (affibodies, diabodies, and nanobodies). An ex-
ample of the latter is given by 68 Gallium HER2 nanobodies,95 
single domain antigen- binding fragments that exhibit rapid tar-
geting and fast blood clearance, high solubility, high stability, easy 
cloning, and modular nature compared to radiolabeled HER2 an-
tibodies. These tactics may result in different distribution relative 
to the therapeutic drug.96,97 Binding of a targeted drug is localized 
onto a specific domain (i.e., epitope). Therefore, the target pres-
ence does not guarantee target engagement. However, opting for 
these approaches may in fact be more suitable for determining the 
expression of pharmacological activity (discussed in the Studying 
Expression of Pharmacological Activity Following Target Binding: 
Illustration and Tools) rather than target engagement. Current 
tools to assess factors that hinder target engagement and the down-
stream pharmacologic effect provide mechanistic insight when pre-
dicting target engagement. However, with the current knowledge 
gap and lack of pharmacological tools to eliminate these factors, we 
can only speculate how assessing drug transporters (e.g., MUC4), 
or other factors may help with dose selection in the future.
Feasibility challenges of executing target engagement imaging 
include the cost of implementing molecular imaging in the clinic 
(imaging equipment, radiolabeled probes, and personnel costs for 
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the required expertise).10,98 A close collaboration among the nu-
clear medicine department, clinical pharmacologists, and medical 
oncologists is needed to implement target engagement imaging. 
In addition, when multicenter studies are performed, evidence 
that the final radiolabeled drug products and manufacturing pro-
cesses are comparable between preparing institutions should be 
provided.98 A multicenter trial like SAKK 56/07, where validated 
PET or MRI scanning technique are applied in multicenter trial 
for response evaluation show that molecular imaging can be ap-
plied in larger populations.99 The widespread use and reimburse-
ment of 18FDG- PET in solid tumor diagnoses and assessment of 
treatment response shows that standardized, radiolabeled tech-
niques are able to influence how we diagnose and treat patients.100 
Given the advances in target engagement imaging, one day target 
imaging may replace some of the current pathology techniques for 
treatment guidance. A clinical trial investigating this hypothesis is 
the IMPACT- MBC (NCT01957332). This study compares the 
impact of FES- PET and 89Zr- trastuzumab–PET with the gold 
standard (tumor biopsy) on treatment decision and outcomes in 
newly diagnosed metastatic breast cancer. The results of this trial 
will show whether target engagement imaging improves treatment 
outcomes compared to standard pathology.
The last level is expression of pharmacological activity following 
target binding, which allows the classification of a drug’s PDs be-
tween proximal (direct measures of target engagement) and distal 
(indirect measures of effect) measurements. A disconnect between 
positive observed target engagement and negative expression of 
pharmacology may suggest a partial understanding of the inter-
connected pathways the drug is expected to modulate, and in turn 
an incomplete understanding of the underlying biology. Currently, 
a variety of detection platforms and assays are used to determine 
pharmacological activity, making validation among platforms 
and between laboratories crucial. Degradation or instability of 
proteins and (micro)RNA may limit the interpretation of the 
data.101 As an example, in the Analysis for Therapy Choice (NCI- 
MATCH), a national signal- finding precision medicine study that 
relies on genomic assays to screen and enroll patients with relapsed 
or refractory cancer after standard treatments, a next- generation 
sequencing RNA and DNA assay was validated in multiple lab-
oratories prior to study onset.102 In contrast, the presence of PD- 
L1 by IHC, which is used to select or stratify patients for PD- 1/
PD- L1- related studies, is not yet standardized and different cut-
off values and scoring systems are used. These factors may explain 
some differences in the correlation between PD- L1 expression and 
outcome seen among studies.103 This suggests a need for standard-
ization and more sensitive and specific diagnostic tests.104
To bring all sources of data together, modeling and simulation 
may be used to perform precision dosing after prospective valida-
tion and clinical implementation. Darwich et al.15 describe ample 
evidence to support the use of MIPD tools to derive therapeu-
tic recommendations for individual patients, but also stress that 
there is little evidence of its use and impact within clinical care. 
Although this review did not specifically address the issue of study-
ing heterogeneity in drug penetration, many of the suggestions to 
improve clinical implementation apply. Examples of improvement 
are the need for extensive model validation; prospective clinical 
evaluation; the perspective of developing MIPD as a companion 
tool together with other diagnostic tools, such as imaging probes 
and other biomarkers in the early stage of drug development.15 
Preclinical information used in these mechanistic models to inform 
personalized cancer treatment may be biased due to lack of trans-
latability between preclinical experiments and patients. Therefore, 
each assumption needs to be validated (e.g., by performing sensi-
tivity analyses or prospective validation). Furthermore, spatiotem-
poral models have not been extensively validated in the clinic, and 
many steps are needed before these models can provide individual-
ized dosing information.
A VISION TO DESIGN PROSPECTIVE CLINICAL TRIALS 
INCLUDING DRUG PENETRATION MEASUREMENTS
Multiple tools have been identified to help inform optimal treat-
ment strategies, (pre)clinical studies provide evidence that drug 
measurements are the key to successful personalized dosing, and 
the key challenges for clinical implementation have been defined, 
so the last step is to discuss optimal implementation of measure-
ments at a systemic, tissue, and cellular/molecular level into clin-
ical oncology practice to create the premise for precision dosing.
We envision that, before treatment, noninvasive imaging- based 
measurements using the radiolabeled drug can assess the presence of 
the target in the target lesion, and the heterogeneity in abundance of 
the target in all lesions (Figure 5, left). In addition, measurements 
related to the tumor microenvironment (e.g., vascularity, hypoxia, 
tumor stiffness, and immune cells) may provide information to pre-
dict drug behavior and allow optimal drug selection. During treat-
ment, performing plasma PK sampling may guide optimal systemic 
exposure and help assessing the maximum binding capacity (Figure 5, 
right). When a biopsy is available during treatment or surgical resec-
tion is performed, this tissue material can be used to visualize drug 
penetration at a microscopic level. Additional imaging during treat-
ment may inform on drug- response and/or drug resistance, either 
through target binding or downstream expression of pharmacology, 
or (preferably) both. The information gathered during treatment 
can be used to decide whether drug dosing should be de- escalated or 
escalated. When this information is integrated with preclinical and 
prior knowledge using multiscale models, this may further support 
adaptation of the treatment decision (Figure 5, bottom).
The use of image- based treatment selection and dose optimi-
zation, as proposed in Figure 5, needs to be supported by pro-
spective studies to: (i) assess whether image- based or standard 
assessment guided treatment provide better outcomes and (ii) as-
sess whether drug doses can be modified according to intratumor 
drug measurements. Freidlin and Korn105 provide the methodolo-
gies to efficiently incorporate such biomarker- driven enrichment 
strategies, with the most efficient example provided by enrichment 
designs, in which only patients who show high target engagement, 
high tissue penetration, and high systemic exposures in imaging 
studies are to be randomized over a new treatment vs. standard 
of care. Furthermore, a Bayesian approach106 can be used to inte-
grate clinical and preclinical data (prior information) to optimally 
inform dosing and speed up decision making. Then, an adaptive 
design can be used to efficiently test optimized dosing strategies 
in patients.
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CONCLUSIONS
Recent advances in technologies at a macroscopic and microscopic 
level improve the visualization and assessment of drug penetra-
tion in solid tumors at the systemic, tumor tissue, and cellular or 
molecular level and the expression of pharmacological activity 
following target engagement. Individual (pre)clinical studies of 
tumor drug penetration measurements to date, although small 
and generally retrospective in nature, suggest that “precision 
dosing” (i.e., personalized dosing based on drug penetration in a 
solid tumor), may improve outcomes in patients. Unambiguous 
assessment of the benefits of precision dosing require clinical in-
vestigation of anticancer drug distribution in randomized trials at 
the four biological levels that we outlined, with the results being 
analyzed using integrative and mechanistic models, including spa-
tial and temporal understanding of drug penetration. This review 
shows that in today’s era of potent targeted drugs, precision dos-
ing remains the missing piece of the current oncology precision 
medicine puzzle.
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